StreetInsider.com News Articles

Form 6-K BetterLife Pharma Inc. For: Sep 14

Tue, 15 Sep 2026 12:11:00 -0400

si-local-file:///var/storage/secattach/20260915/27063728.html

Form 6-K BetterLife Pharma Inc. For: Sep 14

Tue, 15 Sep 2026 12:11:00 -0400

si-local-file:///var/storage/secattach/20260915/27063728.html

Form 6-K BetterLife Pharma Inc. For: Sep 11

Fri, 11 Sep 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260911/27050463.html

Form 6-K BetterLife Pharma Inc. For: Sep 11

Fri, 11 Sep 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260911/27050463.html

BetterLife Pharma names Charles Duncan as director and audit chair

Mon, 31 Aug 2026 08:02:11 -0400

BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) has appointed Charles Duncan, PhD, as a director and chair of its audit committee, the Vancouver-based biotechnology company announced.

Dr. Duncan has nearly 30 years of experience in the biopharmaceutical industry, including roles as a biotechnology analyst at Cantor Fitzgerald, Piper Jaffray and JMP Securities. During his Wall Street career, he initiated research coverage on more than 175 biotechnology companies, evaluated over 200 investment banking transactions and served as senior vetting analyst on approximately 25 initial public offerings.

He currently serves as Managing Director and Head of Biotech Strategy and Development at Gilmartin

BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee

Mon, 31 Aug 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - August 31, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company developing BETR-001 for the treatment of migraine and headache disorders, is pleased to announce the appointment of Charles Duncan, PhD as Director and Chair of the Audit Committee.

Dr. Duncan is a biotechnology strategist, board director and former top-ranked Wall Street biotechnology analyst with nearly 30 years of experience advising investors, management teams and boards across the biopharmaceutical industry. As Managing Director, Head of Biotech Strategy & Development at Gilmartin Group, he provides strategic advisory and

BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee

Mon, 31 Aug 2026 08:00:00 -0400

Form 6-K BetterLife Pharma Inc. For: Aug 24

Mon, 24 Aug 2026 10:00:00 -0400

si-local-file:///var/storage/secattach/20260824/26965496.html

Form 6-K BetterLife Pharma Inc. For: Aug 24

Mon, 24 Aug 2026 10:00:00 -0400

si-local-file:///var/storage/secattach/20260824/26965496.html

Form 6-K BetterLife Pharma Inc. For: Aug 24

Mon, 24 Aug 2026 10:00:00 -0400

si-local-file:///var/storage/secattach/20260824/26965496.html

BetterLife Pharma names neurologist as chief medical officer

Wed, 19 Aug 2026 08:02:10 -0400

BetterLife Pharma Inc. (CSE: BETR, OTCQB: BETRF, FSE: NPAU) has appointed Mahan Chehrenama, DO, as Chief Medical Officer, according to a company statement. Dr. Chehrenama will lead clinical development for BETR-001, the company's non-hallucinogenic neuroplastogen candidate targeting migraine and other headache disorders.

The Vancouver-based biotechnology company is working toward an Investigational New Drug (IND) application for BETR-001, anticipated in the first quarter of 2027.

Dr. Chehrenama is a board-certified neurologist and headache sub-specialist with more than two decades of clinical practice. She most recently served as Chief Medical Officer at Manistee Therapeutics, where she led an IND submission and oversaw Phase 1

BetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical Officer

Wed, 19 Aug 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - August 19, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, today announced the appointment of Mahan Chehrenama, DO, as Chief Medical Officer. Dr. Chehrenama will lead clinical development for BETR-001, the Company's non-hallucinogenic neuroplastogen advancing toward an Investigational New Drug (IND) application for migraine and other headache disorders, anticipated in the first quarter of 2027.

Dr. Chehrenama is a board-certified neurologist and headache sub-specialist who pairs nearly a decade in senior biopharma drug development with more than two decades of clinical practice and research

BetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical Officer

Wed, 19 Aug 2026 08:00:00 -0400

Dr. Chehrenama is a board-certified neurologist and headache sub-specialist who pairs nearly a decade in senior biopharma drug development with more than two decades of clinical practice and research

Form 6-K BetterLife Pharma Inc. For: Aug 03

Wed, 05 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260805/26869401.html

Form 6-K BetterLife Pharma Inc. For: Aug 03

Wed, 05 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260805/26869401.html

Form 6-K BetterLife Pharma Inc. For: Aug 03

Wed, 05 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260805/26869401.html

BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism

Mon, 13 Jul 2026 08:00:00 -0400

Fully non-hallucinogenic, oral, non-scheduled 5-HT2A neuroplastogen differentiates BETR-001 from every other 5-HT2A agonist program; depression and other psychiatric disorders retained as optional future indications

Vancouver, British Columbia--(Newsfile Corp. - July 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), today announced the prioritization of its lead clinical-stage asset, BETR-001, to pursue migraine and other primary headache disorders as its lead indications. The strategic focus concentrates BETR-001's development on one of the largest, most disabling and most underserved areas of neurology, and does so through a serotonin-receptor mechanism of action that is already clinically validated

BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism

Mon, 13 Jul 2026 08:00:00 -0400

BetterLife Pharma adds legal veteran to board, reports warrant proceeds

Thu, 09 Jul 2026 08:02:08 -0400

BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) has appointed John W. LaRocca to its board of directors and audit committee, the Vancouver-based biotechnology company announced.

LaRocca brings roughly 30 years of biopharmaceutical industry experience, having served as chief legal officer, corporate secretary, and founding chief compliance officer at four NYSE- and Nasdaq-listed companies. His prior roles include corporate secretary positions at Y-mAbs Therapeutics, Aerie Pharmaceuticals, and Eagle Pharmaceuticals.

On the transactional side, LaRocca served as principal legal officer on the $930 million sale of Aerie Pharmaceuticals to Alcon Laboratories and the $412 million sale of Y-mAbs Therapeutics to SERB Pharmaceuticals.

BetterLife Pharma Announces Appointment of John W. LaRocca to Board of Directors and Audit Committee

Thu, 09 Jul 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - July 9, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company developing BETR-001 for the treatment of migraine and headache disorders, is pleased to announce the appointment of John W. LaRocca, Esq. to its Board of Directors. Mr. LaRocca will also serve as a member of the Company's Audit Committee.

Mr. LaRocca is a three-decade biopharmaceutical industry executive with extensive public company seasoning across the full life-sciences lifecycle, spanning generics, branded specialty pharma, commercial biotech, and pre-commercial pipeline assets. He has served as Chief Legal Officer, Corporate Secretary,

BetterLife Pharma Announces Appointment of John W. LaRocca to Board of Directors and Audit Committee

Thu, 09 Jul 2026 08:00:00 -0400

BetterLife Pharma hires Nucro-Technics for final BETR-001 toxicology study

Mon, 06 Jul 2026 08:02:13 -0400

BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) has engaged Nucro-Technics Inc. to conduct the final IND-enabling GLP toxicology study for BETR-001, its non-hallucinogenic LSD derivative in preclinical development, according to a press release.

The company projects filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in the first quarter of 2027, which would allow the drug candidate to advance to Phase 1 clinical trials.

BETR-001, chemically known as 2-bromo-lysergic acid diethylamide (2-Br-LSD), is being developed initially for migraine and cluster headache. The compound acts as an agonist of the 5-HT1B, 5-HT1D, 5-HT1F, and 5-HT2A receptors.

"We

BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1

Mon, 06 Jul 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - July 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement with Nucro-Technics Inc. ("Nucro") to conduct the last IND-enabling GLP toxicology study with BETR-001 for its planned IND and Phase 1 program.

BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD. BETR-001 is a potent neuroplastogen and an agonist of the 5-HT1B, 5-HT1D, and 5-HT1F receptors, which are clinically validated targets of migraine therapies, as well as the 5-HT2A receptors. BETR-001 is being developed initially for migraine and cluster headache, two disabling

BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1

Mon, 06 Jul 2026 08:00:00 -0400

Form 6-K BetterLife Pharma Inc. For: Apr 30

Fri, 26 Jun 2026 15:00:00 -0400

si-local-file:///var/storage/secattach/20260626/26698090.html